Skip to main content
. 2017 Nov;15(8):1073–1084. doi: 10.2174/1570159X15666170113100611

Table 4.

Incidence of treatment-emergent adverse events reported by ≥5% of patients assessed using UKU Scale.

Adverse Events Risperidone
(n=21) n (%)
Aripiprazole
(n=13) n (%)
Asthenia * 11(45.9) 0
Sedation 7(29.2) 1(7.7)
Falling memory 2(8.3) 0
Increased duration of sleep 6(25) 1(7.7)
Reduced duration of sleep 2(8.4) 1(7.7)
Rigidity 2(8.4) 0
Hypokinesia* 9(37.5) 0
Hyperkinesias 0 1(7.7)
Tremor 4(16.7) 0
Akathisia 1(4.2) 1(7.7)
Accommodation disturbance 2(8.4) 0
Increased salivation 2(8.4) 0
Constipation 1(4.2) 1(7.7)
Orthostatic dizziness* 4(16.7) 0
Rash 2(8.4) 0
Diminished sexual desire* 4(16.7) 0
Head ache 4(16.7) 1(7.7)

*p≤0.05.